137 related articles for article (PubMed ID: 36998872)
1. Real World Data on Efficacy and Safety of Vismodegib in Greek Patients with Advanced, Multiple and Metastatic Basal Cell Carcinoma.
Sgouros D; Pappa G; Syrmali A; Theodoropoulos K; Theotokoglou S; Bozi E; Damaskou V; Panayiotides IG; Katoulis AC
Indian J Dermatol; 2022; 67(6):796-797. PubMed ID: 36998872
[No Abstract] [Full Text] [Related]
2. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.
Sekulic A; Yoo S; Kudchadkar R; Guillen J; Rogers G; Chang ALS; Guenthner S; Raskin B; Dawson K; Mun Y; Chu L; McKenna E; Lacouture M
PLoS One; 2022; 17(1):e0262151. PubMed ID: 35030185
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina.
Cozzani R; Del Aguila R; Carrizo M; Sanchez S; Gonzalez A;
Int J Dermatol; 2020 May; 59(5):627-632. PubMed ID: 32034775
[TBL] [Abstract][Full Text] [Related]
4. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
[TBL] [Abstract][Full Text] [Related]
5. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
6. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: Retrospective real-life data.
Gürbüz M; Doğan İ; Akkuş E; Ermiş H; Utkan G; Vatansever S; Taş F
Dermatol Ther; 2021 Nov; 34(6):e15122. PubMed ID: 34478210
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
Sekulic A; Migden MR; Oro AE; Dirix L; Lewis KD; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Low JA; Mackey HM; Yauch RL; Graham RA; Reddy JC; Hauschild A
N Engl J Med; 2012 Jun; 366(23):2171-9. PubMed ID: 22670903
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of Vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities.
Spallone G; Sollena P; Ventura A; Fargnoli MC; Gutierrez C; Piccerillo A; Tambone S; Bianchi L; Peris K
Dermatol Ther; 2019 Nov; 32(6):e13108. PubMed ID: 31606940
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany - The non-interventional study NIELS.
Gutzmer R; Schulze HJ; Hauschild A; Leiter U; Meier F; Haferkamp S; Ulrich C; Wahl RU; Berking C; Herbst R; Häckl M; Schadendorf D
J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):1678-1685. PubMed ID: 33931910
[TBL] [Abstract][Full Text] [Related]
11. Vismodegib (ERIVEDGE°) In basal cell carcinoma: too many unknowns.
Prescrire Int; 2015 Jan; 24(156):11-4. PubMed ID: 25729822
[TBL] [Abstract][Full Text] [Related]
12. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
Basset-Séguin N; Hauschild A; Kunstfeld R; Grob J; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Arenberger P; Fife K; Raimundo A; Dika E; Dimier N; Fittipaldo A; Xynos I; Hansson J
Eur J Cancer; 2017 Nov; 86():334-348. PubMed ID: 29073584
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
14. Real-World Experience with Vismodegib on Advanced and Multiple BCCs: Data from the RELIVIS Study.
Ruiz-Salas V; Podlipnik S; Sandoval-Clavijo A; Sanmartin-Jiménez O; Bernia-Petit E; Bonfill-Ortí M; Bassas-Freixas P; Yebenes-Marsal M; Flórez-Menéndez Á; Solá-Ortigosa J; Just-Sarobé M; Aguayo-Ortiz R; Masferrer I Niubó E; Quintana-Codina M; Deza G; Jaka A; Fuentes MJ; Cañueto J; Toll A
Dermatology; 2023; 239(5):685-693. PubMed ID: 37257423
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
[TBL] [Abstract][Full Text] [Related]
16. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
17. Real-World Experience of Vismodegib in Advanced Basal Cell Carcinoma at a Canadian Cancer Center.
Tong J; Mitchell B; Roth K; Logan D; Ernst S
J Cutan Med Surg; 2022; 26(2):143-148. PubMed ID: 34663118
[TBL] [Abstract][Full Text] [Related]
18. Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study.
Verkouteren BJA; Wakkee M; Reyners AKL; Nelemans P; Aarts MJB; Rácz E; Terra JB; Devriese LA; Alers RJ; Kapiteijn E; van Doorn R; Bekkenk MW; Reinders MGHC; Mosterd K
Br J Cancer; 2021 Mar; 124(7):1199-1206. PubMed ID: 33462360
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS.
Kaatz M; Mohr P; Livingstone E; Weichenthal M; Kreuter A; Pföhler C; Leiter U; Ulrich J; Utikal JS; Gutzmer R; Herbst R; Schadendorf D
Acta Derm Venereol; 2022 Apr; 102():adv00695. PubMed ID: 35199180
[TBL] [Abstract][Full Text] [Related]
20. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
